Treatment of Candida glabrata Infections
Initial Therapy Selection
- The Infectious Diseases Society of America recommends an echinocandin (caspofungin, micafungin, or anidulafungin) as the preferred first-line treatment for Candida glabrata infections, particularly in critically ill patients or those with recent azole exposure 1
- Caspofungin is administered at a 70 mg loading dose, then 50 mg daily 1
- Micafungin is administered at 100 mg daily 1
- Anidulafungin is administered at a 200 mg loading dose, then 100 mg daily 1
- The preference for echinocandins over fluconazole stems from C. glabrata's intrinsic reduced susceptibility to azoles and the superior outcomes demonstrated in critically ill patients 2, 3, 4
Alternative Therapies
- Fluconazole 800 mg loading dose, then 400 mg daily may be considered for less critically ill patients without recent azole exposure, but only if susceptibility testing confirms fluconazole susceptibility 1, 2
- Lipid formulation amphotericin B is administered at 3-5 mg/kg daily if intolerance or resistance to other agents 1, 5
- Amphotericin B deoxycholate is administered at 0.5-1.0 mg/kg daily, but is less preferred due to toxicity 2
Susceptibility Testing
- Azole susceptibility testing is mandatory for all C. glabrata isolates from blood and sterile sites 1
- Echinocandin susceptibility testing should be considered in patients with prior echinocandin exposure 1
Step-Down Therapy
- Transition from echinocandin to oral azole therapy requires documented susceptibility and clinical stability 1, 2
- For fluconazole-susceptible isolates, transition to fluconazole 800 mg (12 mg/kg) daily after 5-7 days if clinically stable with negative repeat cultures 1
- For voriconazole-susceptible isolates, voriconazole 200-300 mg (3-4 mg/kg) twice daily is an option 1
Site-Specific Considerations
- For fluconazole-susceptible C. glabrata cystitis, oral fluconazole 200 mg daily for 2 weeks is recommended 6
- For fluconazole-resistant C. glabrata, amphotericin B deoxycholate 0.3-0.6 mg/kg daily for 1-7 days or oral flucytosine 25 mg/kg four times daily for 7-10 days is recommended 6
- Remove or replace indwelling catheters when feasible 6
Candidemia Management
- Continue therapy for 2 weeks after documented clearance from bloodstream and resolution of symptoms 1, 2
- Perform daily or every other day follow-up cultures until clearance is documented 1
- Remove central venous catheters in non-neutropenic patients 2, 7
- Conduct a dilated ophthalmologic examination within the first week after diagnosis 1
Treatment Duration and Monitoring
- Minimum treatment duration is 2 weeks after blood culture clearance and symptom resolution 1, 2
- Deep tissue infections require longer courses based on site and response 6
First‑Line and Management Strategies for Invasive Candida glabrata Infections
First‑Line Antifungal Therapy
Dosing Regimens (Evidence from randomized trials, ~75 % success)
| Agent | Loading Dose | Daily Maintenance Dose | Route |
|---|---|---|---|
| Caspofungin | 70 mg IV | 50 mg IV daily | Intravenous |
| Micafungin | – | 100 mg IV daily | Intravenous |
| Anidulafungin | 200 mg IV | 100 mg IV daily | Intravenous |
All dosing recommendations are derived from the same clinical evidence base【8】.
Patient Populations in Which Echinocandins Are Critical
Role of Fluconazole and Mandatory Susceptibility Testing
Step‑Down Therapy Criteria
Alternative Antifungal Options (When Echinocandins Are Intolerant or Unavailable)
Source‑Control Measures
Treatment Duration and Monitoring
Management of Candida glabrata Infections
First‑Line Therapy: Echinocandins
- Echinocandins (caspofungin, micafungin, anidulafungin) are the preferred first‑line agents for C. glabrata infections, especially in moderately severe to severe illness, recent azole exposure, or when azole resistance is suspected. Strong recommendation. 10, 11
- C. glabrata exhibits intrinsic reduced susceptibility to azoles and echinocandins provide superior fungicidal activity. Strong recommendation. 10
Recommended Dosing Regimens
| Drug | Loading Dose | Maintenance Dose |
|---|---|---|
| Caspofungin | 70 mg IV | 50 mg IV daily |
| Micafungin | – | 100 mg IV daily |
| Anidulafungin | 200 mg IV | 100 mg IV daily |
Clinical Situations Requiring Echinocandin Use
- Hemodynamically unstable or severely ill patients (moderate to severe disease). Strong recommendation. 10, 11
- Recent azole exposure within the past 3 months. Strong recommendation. 10, 12, 11
- Critically ill patients in intensive‑care settings. Strong recommendation. 10, 11
- Patients at high risk for fluconazole‑resistant Candida species. Strong recommendation. 12, 13
Alternative Therapy: High‑Dose Fluconazole (Conditional)
- Fluconazole may be used only in less critically ill patients without recent azole exposure, and only after documented susceptibility testing confirms fluconazole susceptibility. Conditional recommendation. 10, 11
- Fluconazole dosing: 800 mg (≈12 mg/kg) loading dose, then 400 mg (≈6 mg/kg) daily. 10, 11
- Azole susceptibility testing must be performed on all C. glabrata blood and sterile‑site isolates before initiating azole therapy. Mandatory. 12
Step‑Down Therapy (Echinocandin → Oral Azole)
- Transition to oral fluconazole is not recommended without confirmed susceptibility results. Strong recommendation. 10, 11
- Criteria for safe step‑down (all must be met):
Second‑Line Alternatives (When Echinocandins Unavailable or Intolerant)
- Liposomal amphotericin B (LFAmB) 3–5 mg/kg IV daily – preferred formulation due to lower toxicity. Strong recommendation. 10, 11
- Amphotericin B deoxycholate 0.5–1.0 mg/kg IV daily – higher toxicity risk. Conditional recommendation. 10, 13, 11
- LFAmB is effective but considered less attractive than echinocandins for C. glabrata. 10, 11
Source‑Control Measures
- Removal of central venous catheters is strongly recommended for all non‑neutropenic patients with C. glabrata candidemia. Strong recommendation. 10, 12, 11
- Catheter removal should occur as early as possible when the source is presumed catheter‑related and removal can be performed safely. Strong recommendation. 10, 12
- In neutropenic patients, catheter removal should be individualized. Conditional recommendation. 12, 13
Treatment Duration & Monitoring
- Antifungal therapy should continue for at least 2 weeks after documented clearance of Candida from the bloodstream and complete resolution of symptoms. Strong recommendation. 10, 11
- Monitoring:
Special Populations
Pregnancy
- Amphotericin B deoxycholate is the treatment of choice for pregnant women with C. glabrata infections because of its established safety profile in pregnancy. Strong recommendation. 12, 13
Neutropenic Patients
- Echinocandins remain the first‑line agents. Strong recommendation. 13, 11
- Catheter removal should be individualized. Conditional recommendation. 13
- Treatment duration extends until neutropenia resolves. Strong recommendation. 10, 11
Common Pitfalls to Avoid
- Using fluconazole empirically without susceptibility data leads to treatment failure. Strong recommendation to avoid. 10
- Failing to remove central venous catheters in non‑neutropenic patients increases risk of persistent infection. Strong recommendation to avoid. 10
- Stepping down to azole therapy before confirming susceptibility and clinical stability compromises outcomes. Strong recommendation to avoid. 10, 11
- Inadequate treatment duration (stopping before 2 weeks post‑clearance) results in higher relapse rates. Strong recommendation to avoid. 10, 11
- Not performing follow‑up blood cultures to document clearance impedes assessment of therapeutic success. Strong recommendation to avoid. 12
When risk factors such as prior fluconazole use, diabetes, or presence of a central venous catheter are present, empiric echinocandin therapy becomes even more critical. Strong recommendation. 12